These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 21516558)

  • 1. How well do multiple testing methods scale up when both n and k increase?
    Westfall PH; Manage A
    J Biopharm Stat; 2011 Jul; 21(4):583-94. PubMed ID: 21516558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. On sample size determination in multi-armed confirmatory adaptive designs.
    Wassmer G
    J Biopharm Stat; 2011 Jul; 21(4):802-17. PubMed ID: 21516570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple hypotheses testing based on ordered p values--a historical survey with applications to medical research.
    Hommel G; Bretz F; Maurer W
    J Biopharm Stat; 2011 Jul; 21(4):595-609. PubMed ID: 21516559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sample size determination for the false discovery rate.
    Pounds S; Cheng C
    Bioinformatics; 2005 Dec; 21(23):4263-71. PubMed ID: 16204346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sample size determination in superiority clinical trials with multiple co-primary correlated endpoints.
    Sozu T; Sugimoto T; Hamasaki T
    J Biopharm Stat; 2011 Jul; 21(4):650-68. PubMed ID: 21516562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Issues of simultaneous tests for noninferiority and superiority.
    Ng TH
    J Biopharm Stat; 2003 Nov; 13(4):629-39; discussion 641-62. PubMed ID: 14584713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Empirical Bayes screening of many p-values with applications to microarray studies.
    Datta S; Datta S
    Bioinformatics; 2005 May; 21(9):1987-94. PubMed ID: 15691856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Power and sample size when multiple endpoints are considered.
    Senn S; Bretz F
    Pharm Stat; 2007; 6(3):161-70. PubMed ID: 17674404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Partitioning to uncover conditions for permutation tests to control multiple testing error rates.
    Calian V; Li D; Hsu JC
    Biom J; 2008 Oct; 50(5):756-66. PubMed ID: 18932135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Properties of multiple intersection-union tests for multiple endpoints in combination therapy trials.
    Westfall PH; Ho SY; Prillaman BA
    J Biopharm Stat; 2001; 11(3):125-38. PubMed ID: 11725927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of seven methods for producing Affymetrix expression scores based on False Discovery Rates in disease profiling data.
    Shedden K; Chen W; Kuick R; Ghosh D; Macdonald J; Cho KR; Giordano TJ; Gruber SB; Fearon ER; Taylor JM; Hanash S
    BMC Bioinformatics; 2005 Feb; 6():26. PubMed ID: 15705192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three methods for constructing parallel gatekeeping procedures in clinical trials.
    Dmitrienko A; Soulakova JN; Millen BA
    J Biopharm Stat; 2011 Jul; 21(4):768-86. PubMed ID: 21516568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of a statistical equivalence test applied to microarray data.
    Qiu J; Cui X
    J Biopharm Stat; 2010 Mar; 20(2):240-66. PubMed ID: 20309757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sample size calculation for the van Elteren test adjusting for ties.
    Zhao YD; Rahardja D; Mei Y
    J Biopharm Stat; 2008; 18(6):1112-9. PubMed ID: 18991111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quick calculation for sample size while controlling false discovery rate with application to microarray analysis.
    Liu P; Hwang JT
    Bioinformatics; 2007 Mar; 23(6):739-46. PubMed ID: 17237060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the statistical power for multiple tests: a case study.
    Yeo A; Qu Y
    Pharm Stat; 2009; 8(1):5-11. PubMed ID: 18381588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sample size re-estimation for adaptive sequential design in clinical trials.
    Gao P; Ware JH; Mehta C
    J Biopharm Stat; 2008; 18(6):1184-96. PubMed ID: 18991116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sample size for FDR-control in microarray data analysis.
    Jung SH
    Bioinformatics; 2005 Jul; 21(14):3097-104. PubMed ID: 15845654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Test for the consistency of noninferiority from multiple clinical trials.
    Yan X; Wang MC; Su X
    J Biopharm Stat; 2007; 17(2):265-78. PubMed ID: 17365223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiplicity-adjusted sample size requirements: a strategy to maintain statistical power with Bonferroni adjustments.
    Leon AC
    J Clin Psychiatry; 2004 Nov; 65(11):1511-4. PubMed ID: 15554764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.